Cargando…
Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
Inhibition of the papain-like protease (PLpro) of SARS-CoV-2 has been demonstrated to be a successful target to prevent the spreading of the coronavirus in the infected body. In this regard, covalent inhibitors, such as the recently proposed VIR251 ligand, can irreversibly inactivate PLpro by formin...
Autores principales: | Hognon, Cécilia, Marazzi, Marco, García-Iriepa, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143025/ https://www.ncbi.nlm.nih.gov/pubmed/35628665 http://dx.doi.org/10.3390/ijms23105855 |
Ejemplares similares
-
Revealing the Molecular Interactions between Human ACE2 and the Receptor Binding Domain of the SARS-CoV-2 Wild-Type, Alpha and Delta Variants
por: Hognon, Cécilia, et al.
Publicado: (2023) -
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022) -
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022) -
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
por: Sanders, Brian C., et al.
Publicado: (2023) -
Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease: Parthenolide covalently inhibits papain-like protease
por: Zou, Zhihui, et al.
Publicado: (2022)